Behold.ai red dot® v2 evaluation

• Research type

  Research Study

• Full title

  A mixed methods study to assess the clinical effectiveness and acceptability of behold.ai red dot® v2 artificial intelligence software to prioritise chest X-ray (CXR) interpretation

• IRAS ID

  314529

• Contact name

  David J Lowe

• Contact email

  david.lowe@ggc.scot.nhs.uk

• Sponsor organisation

  NHS Greater Glasgow and Clyde

• Duration of Study in the UK

  1 years, 4 months, 1 days

• Research summary

  Lung cancer is the most common cause of cancer death in the UK, yet compared to Europe it has low survival rates. The NHS aims to find 75% of cancers at an early stage as this can improve the chances of survival. To support this target, behold.ai have worked to develop the UK-approved red dot®v2 Artificial Intelligence (AI) algorithm, which is a software program that can analyse X-rays to identify lung cancers, and on it's own identify and generate a report for normal examinations.

  The project includes four elements:-

  1. A stepped wedge randomised clinical effectiveness study - to assess the effectiveness and safety of the AI software.

  2. A technical evaluation - to test the performance of the AI software

  3. Health economic evaluation - To check the cost benefits of the AI.

  4. Qualitative evaluation - to assess acceptability with staff and patients.
  

• REC name

  Yorkshire & The Humber - Leeds West Research Ethics Committee

• REC reference

  22/YH/0151

• Date of REC Opinion

  20 Jul 2022

• REC opinion

  Favourable Opinion